Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 154 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Could Cholesterol-Lowering Drugs Improve Cancer Immunotherapy? December 10, 2020 Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 Load more HOT NEWS Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer... Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... Glioblastoma Study Highlights Sex Differences in Brain Cancer
